Our report showed that SC66, an Akt inhibitor, was found to inhibit the proliferation of various human ovarian cancer cells in vitro, and the sensitivity of ovarian cancer cells to SC66 was negatively correlated with the content of COL11A1 in cells. This evidence concerns the gene AKT1 and ovarian carcinoma.